Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$1.00 USD
+0.04 (4.08%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $0.99 -0.01 (-0.92%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Income Statements
Fiscal Year end for Seres Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 126 | 7 | 145 | 33 | 35 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 126 | 7 | 145 | 33 | 35 |
Selling & Adminstrative & Depr. & Amort Expenses | 234 | 254 | 209 | 121 | 106 |
Income After Depreciation & Amortization | -108 | -246 | -64 | -88 | -72 |
Non-Operating Income | 7 | 2 | 2 | 2 | 2 |
Interest Expense | 13 | 6 | 3 | 3 | 1 |
Pretax Income | -114 | -250 | -66 | -89 | -70 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -114 | -250 | -66 | -89 | -70 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -114 | -250 | -66 | -89 | -70 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -101 | -238 | -56 | -81 | -64 |
Depreciation & Amortization (Cash Flow) | 7 | 8 | 9 | 8 | 7 |
Income After Depreciation & Amortization | -108 | -246 | -64 | -88 | -72 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 128.00 | 108.08 | 91.70 | 79.79 | 56.65 |
Diluted EPS Before Non-Recurring Items | -0.89 | -2.31 | -0.72 | -1.12 | -1.20 |
Diluted Net EPS (GAAP) | -0.89 | -2.31 | -0.72 | -1.12 | -1.24 |
Fiscal Year end for Seres Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.06 | 0.31 | 126.47 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.06 | 0.31 | 126.47 |
SG&A, R&D, and Dept/Amort Expenses | 31.35 | 39.58 | 39.59 | 47.72 | 76.95 |
Income After SG&A, R&D, and Dept/Amort Expenses | -31.35 | -39.58 | -39.53 | -47.41 | 49.52 |
Non-Operating Income | 1.92 | 4.12 | 2.31 | 3.57 | 0.21 |
Interest Expense | 3.45 | 4.66 | 4.03 | 4.01 | 3.19 |
Pretax Income | -32.87 | -40.13 | -41.25 | -47.85 | 46.55 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -32.87 | -40.13 | -41.25 | -47.85 | 46.55 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -32.87 | -40.13 | -41.25 | -47.85 | 46.55 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 151.52 | 146.10 | 128.00 | 128.29 | 129.85 |
Diluted EPS Before Non-Recurring Items | -0.22 | -0.27 | -0.32 | -0.37 | 0.36 |
Diluted Net EPS (GAAP) | -0.22 | -0.27 | -0.31 | -0.37 | 0.36 |